Drugmaker GSK buys US cancer firm for $1.9 bn

GlaxoSmithKline on Wednesday said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion as the British drugs giant restructures.


Study finds key GSK-Theravance lung drug didn't extend lives

A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative—but declining—medicine ...

Diseases, Conditions, Syndromes

Glaxo plant with Legionnaires' bacteria is quiet for second day

All was quiet Wednesday at a GlaxoSmithKline pharmaceutical plant that was shut down after the drug maker discovered the bacteria that cause potentially fatal Legionnaires' disease in a cooling tower at the site.


GlaxoSmithKline opts to hold on to HIV business

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

page 1 from 18


GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a United Kingdom-based pharmaceutical, biological, and healthcare company. GSK is the world's second largest pharmaceutical company and a research-based company with a wide portfolio of pharmaceutical products covering anti-infectives, central nervous system, respiratory, gastro-intestinal/metabolic, oncology, and vaccines products. It also has a Consumer Healthcare operation comprising leading oral healthcare products, nutritional drinks, and over the counter medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 100 Index.

This text uses material from Wikipedia, licensed under CC BY-SA